GlucoSentient

GlucoSentient, Inc. is a healthcare technology company that specializes in transforming personal blood glucose meters (BGM) into versatile, point-of-care diagnostic platforms. By utilizing patent-pending DNAzyme-based technology, the company’s platform translates the presence of non-glucose targets—such as therapeutic drugs, protein markers, nucleic acids, and heavy metal ions—into a measurable glucose signal that can be quantified using standard, widely available glucose meter hardware. This approach leverages the established affordability, simplicity, and compact design of existing BGM systems to enable rapid, low-cost diagnostic testing for a range of applications, including environmental monitoring and clinical diagnostics.

The technology is designed to address critical gaps in healthcare access, particularly in resource-limited settings where traditional laboratory analysis is impractical. By enabling at-home or point-of-care testing, GlucoSentient aims to improve treatment adherence and outcomes for patients managing conditions like tuberculosis or oral cancer, where consistent therapeutic drug or biomarker monitoring is essential. The company, founded in 2011 and based in Champaign, Illinois, has received support from various Small Business Innovation Research (SBIR) grants to develop these monitoring systems. Their work emphasizes proactive health management and personalized medicine through accessible, cost-effective diagnostic tools that simplify complex laboratory procedures into user-friendly, portable tests.